微小RNA-106b通过靶向基质金属蛋白酶2影响滋养细胞侵袭与增殖
该研究检测了轻度子痫前期(mPE,n=30)、重度子痫前期(sPE,n=30)和正常孕妇(n=40)胎盘组织中miR-106b与MMP-2的表达,并在JAR和JEG3细胞中验证miR-106b靶向MMP-2对侵袭和增殖的影响。结果显示miR-106b在mPE和sPE胎盘中表达升高而MMP-2降低,miR-106b模拟物抑制细胞增殖与侵袭,抑制物则促进。结论认为miR-106b通过靶向MMP-2抑制JAR和JEG3细胞侵袭增殖,与子痫前期发病相关。
要点
- mPE和sPE胎盘miR-106b表达分别为2.89±0.04和1.96±0.03,均高于正常孕妇的1.01±0.03(P<0.05)。
- mPE和sPE胎盘MMP-2 mRNA分别为1.87±0.05和0.69±0.03,均低于正常孕妇的2.78±0.03(P<0.05)。
- miR-106b模拟物组JAR和JEG3穿膜细胞数均低于模拟物对照组,抑制物组均高于抑制物对照组(P<0.05)。
核心结论
- miR-106b能够通过靶向调控MMP-2的表达抑制JAR细胞和JEG3细胞的侵袭、增殖,与子痫前期的发病相关。
研究设计与样本
- 收集轻度子痫前期(mPE,n=30)、重度子痫前期(sPE,n=30)和正常孕妇(n=40)的胎盘组织。
- 将绒毛膜癌细胞系JAR细胞和JEG3细胞各分为miR-106b模拟物组、模拟物对照组、miR-106b抑制物组、抑制物对照组。
- 采用荧光素酶报告基因活性检测法验证miR-106b对MMP-2的调控,采用实时荧光定量PCR和蛋白印迹法检测表达,MTT法检测增殖,体外侵袭实验检测侵袭力。
主要发现
- 荧光素酶报告基因活性检测显示,含miR-106b质粒和含MMP-2基因重组质粒共同转染JAR和JEG3细胞后,与模拟物对照比较荧光素酶水平下降(P<0.01)。
- 胎盘组织miR-106b表达在mPE组为2.89±0.04、sPE组为1.96±0.03、正常孕妇组为1.01±0.03,3组比较差异有统计学意义(P<0.05)。
- 胎盘组织MMP-2 mRNA表达在mPE组为1.87±0.05、sPE组为0.69±0.03、正常孕妇组为2.78±0.03,3组比较差异有统计学意义(P<0.05);MMP-2蛋白表达分别为1.63±0.04、0.55±0.03、2.82±0.03(P<0.05)。
- JAR细胞miR-106b表达在模拟物组、模拟物对照组、抑制物组、抑制物对照组分别为2.39±0.03、1.03±0.04、0.73±0.03、1.11±0.04,JEG3细胞分别为2.17±0.04、1.18±0.04、0.61±0.03、1.22±0.03(P<0.05)。
- JAR细胞MMP-2 mRNA在4组分别为0.45±0.15、1.02±0.03、2.28±0.03、1.11±0.03,JEG3细胞分别为0.58±0.03、1.25±0.15、2.25±0.03、1.21±0.03(P<0.05)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the expression of microRNA-106b (miR-106b) in the placentas of patients with pre-eclampsia and its relationship with matrix metallopeptidase (MMP) -2, and its effect on the invasion and proliferation of trophoblasts. Methods: (1) Placental tissues were collected from patients with mild pre-eclampsia (mPE, n=30), severe pre-eclampsia (sPE, n=30) and normal pregnant women (n=40). Human choriocarcinoma cell lines JAR and JEG3 were assigned to the miR-106b mimics group, the mimics negative control group, the miR-106b inhibitor group and the inhibitor negative control group, respectively. (2) The target gene of miR-106b(such as MMP-2) was predicted by bioinformatics. Dual-luciferase reporting system was used to verify the regulation of miR-106b on the expression of MMP-2. (3) The expressions of miR-106b and MMP-2 were measured by quantitative real-time PCR (qRT-PCR) and western blot. (4) Cell proliferation was determined by MTT assay. (5) Invasive activities in each group were assessed by cell transwell invasion assays. Results: (1) Predicting result of bioinformatics indicated that MMP-2 was one of the target genes of miR-106b. Dual-luciferase activity assay demonstrated that MMP-2 was the direct target of miR-106b (P<0.01) .(2) The results of qRT-PCR.①The expression of miR-106b in the placentas of mPE, sPE, normal pregnant women were 2.89±0.04, 1.96±0.03, 1.01±0.03, respectively (P<0.05). And the expression of MMP-2 mRNA in the placentas of mPE, sPE, normal pregnant women were 1.87±0.05, 0.69±0.03, 2.78±0.03, respectively (P<0.05). ②The expression of miR-106b in the JAR cell line in the miR-106b mimics group, the mimics negative control group, the miR-106b inhibitor group and the inhibitor negative control group were 2.39±0.03, 1.03±0.04, 0.73±0.03, 1.11±0.04, respectively (P<0.05). And its expression in the JEG3 cell line were 2.17±0.04, 1.18±0.04, 0.61±0.03 and 1.22±0.03, respectively (P<0.05). ③The expression of MMP-2 mRNA in the JAR cell line in the miR-106b mimics group, the mimics negative control group, the miR-106b inhibitor group and the inhibitor negative control group were 0.45±0.15, 1.02±0.03, 2.28±0.03, 1.11±0.03, respectively (P<0.05). And its expression in the JEG3 cell line were 0.58±0.03, 1.25±0.15, 2.25±0.03, 1.21±0.03, respectively (P<0.05). (3) The results of western blot. ①The expression of MMP-2 protein in the placentas of mPE, sPE, normal pregnant women were 1.63±0.04, 0.55±0.03, 2.82±0.03, respectively (P<0.05). ②The expression of MMP-2 protein in the JAR cell line in the miR-106b mimics group, the mimics negative control group, the miR-106b inhibitor group and the inhibitor negative control group were 0.41±0.03, 0.97±0.03, 2.25±0.03, 1.01±0.03, respectively (P<0.05). And its expression in the JEG3 cell line were 0.53±0.03, 1.20±0.03, 2.31±0.04, 1.19±0.03, respectively (P<0.05). (4) miR-106b could inhibit the proliferation of JAR and JEG3 cells, cell proliferation rates in the miR-106b mimics group were lower than that in the mimics negative control group (P<0.05). And cell proliferation rate in the miR-106b inhibitor group was higher than the inhibitor negative control group (P<0.05). (5) The numbers of JAR cell that passed the membrane in the miR-106b mimics group, the mimics negative control group. The miR-106b inhibitor group and the inhibitor negative control group were 61±15, 79±13, 134±13, 80±12, respectively(P<0.05). And the numbers of JEG3 cell that passed were 57±12, 71±15, 128±15, 70±14, respectively (P<0.05). Conclusion: The miR-106b could inhibit the invasion and proliferation of JAR and JEG3 cells through targeting MMP-2, and have a relationship with the pathogenesis of pre-eclampsia. 目的: 探讨子痫前期孕妇的胎盘组织中微小RNA-106b(miR-106b)、基质金属蛋白酶2(MMP-2)的表达及miR-106b靶向调控MMP-2的表达对滋养细胞侵袭和增殖的影响。 方法: 共纳入30例轻度子痫前期(mPE)、30例重度子痫前期(sPE)和40例正常孕妇,分别为mPE组、sPE组及对照组,收集其胎盘组织;将绒毛膜癌细胞系JAR细胞和JEG3细胞各分为4组(miR-106b模拟物组、模拟物对照组、miR-106b抑制物组、抑制物对照组)。采用荧光素酶报告基因活性检测法验证miR-106b对其靶基因MMP-2基因表达的调控作用;采用实时荧光定量PCR技术、蛋白印迹法检测3组孕妇的胎盘组织和各组细胞中miR-106b和MMP-2 mRNA、蛋白的表达水平;并采用四甲基偶氮唑蓝(MTT)比色法检测各组细胞的相对增殖率,采用体外侵袭实验检测各组细胞的侵袭力。 结果: (1)荧光素酶报告基因活性检测法显示,含miR-106b的质粒和含MMP-2基因的重组质粒共同转染JAR细胞和JEG3细胞后,与模拟物对照比较,其荧光素酶水平下降(P<0.01)。(2)实时荧光定量PCR技术显示:①mPE组、sPE组及对照组孕妇的胎盘组织中,miR-106b和MMP-2 mRNA的表达水平分别为2.89±0.04、1.96±0.03、1.01±0.03,1.87±0.05、0.69±0.03、2.78±0.03,3组分别比较,差异均有统计学意义(P<0.05)。② 4组JAR细胞和4组JEG3细胞(miR-106b模拟物组、模拟物对照组、miR-106b抑制物、抑制物对照组)的miR-106b的表达水平分别为2.39±0.03、1.03±0.04、0.73±0.03、1.11±0.04,2.17±0.04、1.18±0.04、0.61±0.03、1.22±0.03,JAR、JEG3细胞4组间分别比较,差异有统计学意义(P<0.05)。③4组JAR细胞和4组JEG3细胞的MMP-2 mRNA的表达水平分别为0.45±0.15、1.02±0.03、2.28±0.03、1.11±0.03,0.58±0.03、1.25±0.15、2.25±0.03、1.21±0.03,JAR、JEG3细胞的4组间分别比较,差异有统计学意义(P<0.05)。(3)蛋白印迹法显示:①3组孕妇胎盘组织中MMP-2蛋白的表达水平分别为1.63±0.04、0.55±0.03、2.82±0.03,3组比较,差异有统计学意义(P<0.05)。②4组JAR细胞的MMP-2蛋白表达水平分别为0.41±0.03、0.97±0.03、2.25±0.03、1.01±0.03,4组比较,差异有统计学意义(P<0.05)。③4组JEG3细胞的MMP-2蛋白表达水平分别为0.53±0.03、1.20±0.03、2.31±0.04、1.19±0.03,差异有统计学意义(P<0.05)。(4)MTT法检测显示:JAR细胞和JEG3细胞经miR-106b模拟物转染后(即miR-106b模拟物组)细胞增殖率均明显低于相应模拟物对照组,差异有统计学意义(P均<0.05);经miR-106b抑制物转染后(即miR-106b抑制物组)细胞增殖率均明显高于相应的抑制物对照组,差异有统计学意义(P均<0.05)。(5)体外侵袭实验显示:①4组JAR细胞的穿膜细胞数分别为(61±15)、(79±13)、(134±13)、(80±12)个,差异有统计学意义(P<0.05);②4组JEG3细胞的穿膜细胞数分别为(57±12)、(71±15)、(128±15)、(70±14)个,差异有统计学意义(P<0.05)。 结论: miR-106b能够通过靶向调控MMP-2的表达抑制JAR细胞和JEG3细胞的侵袭、增殖,与子痫前期的发病相关。.
引用
- Li J, Wang JM, Liu YH, et al. [Effect of microRNA-106b on the invasion and proliferation of trophoblasts through targeting MMP-2]. Zhonghua Fu Chan Ke Za Zhi. 2017. PMID: 28545271. doi:10.3760/cma.j.issn.0529-567X.2017.05.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。